358 related articles for article (PubMed ID: 33342753)
21. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
Kim JH; Baek YH; Lee H; Choe YJ; Shin HJ; Shin JY
Epidemiol Health; 2021; 43():e2021004. PubMed ID: 33445824
[TBL] [Abstract][Full Text] [Related]
23. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
[TBL] [Abstract][Full Text] [Related]
24. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ;
Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123
[TBL] [Abstract][Full Text] [Related]
25. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
[TBL] [Abstract][Full Text] [Related]
26. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.
Armstrong K; Soltoff A; Rieu-Werden M; Metlay J; Haas J
PLoS One; 2021; 16(3):e0247548. PubMed ID: 33651840
[TBL] [Abstract][Full Text] [Related]
27. Association between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and community-acquired pneumonia: A nationwide population propensity-score matching study.
Lin SY; Chang SS; Lin CL; Lin CC; Hsu WH; Chou CH; Chi CY; Lin CD; Tu CY; Hsu CY; Kao CH
Int J Clin Pract; 2021 Oct; 75(10):e14476. PubMed ID: 34107133
[TBL] [Abstract][Full Text] [Related]
28. Relation Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Severity.
Alhaddad MJ; Almulaify MS; Alshabib AA; Alwesaibi AA; Alkhameys MA; Alsenan ZK; Alsheef HJ; Alsaghirat MA; Almomtan MS; Alshakhs MN
Cureus; 2022 Mar; 14(3):e22903. PubMed ID: 35399441
[TBL] [Abstract][Full Text] [Related]
29. The Association Between COVID-19 Mortality and ICU Admission Rates and Prior History of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hospitalized COVID-19 Patients With Hypertension in Michigan.
Elhouderi E; Elsawalhy E; Al-Sudani N; Mahmood I; Sengstock D
Cureus; 2023 Aug; 15(8):e43980. PubMed ID: 37746496
[TBL] [Abstract][Full Text] [Related]
30. Renin-Angiotensin-Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease.
Murphy DP; Wolfson J; Reule S; Johansen KL; Ishani A; Drawz PE
J Am Soc Nephrol; 2023 Oct; 34(10):1721-1732. PubMed ID: 37545022
[TBL] [Abstract][Full Text] [Related]
31. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
Kunutsor SK; Blom AW; Whitehouse MR; Kehoe PG; Laukkanen JA
Eur J Epidemiol; 2017 Nov; 32(11):947-959. PubMed ID: 28752198
[TBL] [Abstract][Full Text] [Related]
32. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.
Sato K; White N; Fanning JP; Obonyo N; Yamashita MH; Appadurai V; Ciullo A; May M; Worku ET; Helms L; Ohshimo S; Juzar DA; Suen JY; Bassi GL; Fraser JF; Arora RC;
BMC Cardiovasc Disord; 2022 Mar; 22(1):123. PubMed ID: 35321649
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
Rizk JG; Wenziger C; Tran D; Hashemi L; Moradi H; Streja E; Ahluwalia A
Drugs; 2022 Jan; 82(1):43-54. PubMed ID: 34914085
[TBL] [Abstract][Full Text] [Related]
34. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Kurdi A; Abutheraa N; Akil L; Godman B
Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative.
Reding KW; Aragaki AK; Cheng RK; Barac A; Wassertheil-Smoller S; Chubak J; Limacher MC; Hundley WG; D'Agostino R; Vitolins MZ; Brasky TM; Habel LA; Chow EJ; Jackson RD; Chen C; Morgenroth A; Barrington WE; Banegas M; Barnhart M; Chlebowski RT
Oncologist; 2020 Aug; 25(8):712-721. PubMed ID: 32250503
[TBL] [Abstract][Full Text] [Related]
36. First line drug treatment for hypertension and reductions in blood pressure according to age and ethnicity: cohort study in UK primary care.
Sinnott SJ; Douglas IJ; Smeeth L; Williamson E; Tomlinson LA
BMJ; 2020 Nov; 371():m4080. PubMed ID: 33208355
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
Zhang L; Zeng X; Fu P; Wu HM
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
[TBL] [Abstract][Full Text] [Related]
38. Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes.
Nishida Y; Takahashi Y; Nakayama T; Asai S
Cardiovasc Diabetol; 2012 May; 11():53. PubMed ID: 22594344
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An J; Niu F; Sim JJ
Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]